Research reveals standard treatment for ovarian cancer

February 26, 2016

Research led by a Dignity Health St. Joseph's Hospital and Medical Center physician on ovarian cancer was published in the Feb. 24, 2016 issue of New England Journal of Medicine. The research was directed by Bradley J. Monk, M.D. and researchers at 12 other medical facilities around the nation.

The featured research titled "Every-3-Week vs. Weekly Paclitaxel and Carboplatin for Ovarian Cancer" unveils that the standard front-line treatment for advanced should either be every three week chemotherapy with carboplatin, paclitaxel plus bevacizumab (an antibody than inhibits blood vessels from feeding the cancer) or every three week chemotherapy with carboplatin and weekly dose intense paclitaxel. The latter does not involve expensive bevacizumab known as Avastin but is more inconvenient.

"This supports the use of weekly chemotherapy without bevacizumab in treating advanced ovarian cancer," says Dr. Monk who is Director, Division of Gynecologic Oncology Vice Chair, Department of Obstetrics and Gynecology University of Arizona Cancer Center at St. Joseph's Hospital and senior author of the publication.

The research was funded by NRG Oncology (formerly the Gynecologic Oncocolgy Group) which is part of the National Institutes of Health and enrolled patients at cancer centers around the country. Many women with ovarian cancer at the University of Arizona Cancer Center at St. Joseph's Hospital participated in this study.

Importantly, this study did not investigate intraperitoneal chemotherapy (IP) where the chemotherapy is infused directly into the belly. Many believe that the regimen of dose intense weekly chemotherapy supported by the current publication capitalizes on the same key components of IP namely higher doses and weekly administration. However, the intravenous recipe supported by this publication does did not show the intense side effects seen with IP treatments.

This advance is only a small step forward as newer appraises to ovarian cancer are being developed at University of Arizona Cancer Center at St. Joseph's Hospital. For example, doctors are studying a unique class of drugs called PARP inhibitors as well as immunotherapy. The latter uses recently discovered approaches to re-programming a woman's immune system to recognize and fight her ovarian cancer. Such drugs have recently been FDA approved to treat lung cancer and melanoma.

Explore further: Promising cervical cancer study

Related Stories

Promising cervical cancer study

February 21, 2014

Research on cervical cancer performed by a physician at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center has been published in the New England Journal of Medicine. The multi-site research ...

Researcher discovers ovarian cancer treatment

June 19, 2014

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the ...

Intraperitoneal chemotherapy ups ovarian cancer outcomes

August 5, 2015

(HealthDay)—Intraperitoneal chemotherapy significantly improves survival among women with advanced ovarian cancer; however, fewer than half of eligible U.S. patients are receiving it, according to research published online ...

Recommended for you

Taking control of key protein stifles cancer spread in mice

May 20, 2016

For cancer to spread, the cells that take off into the bloodstream must find a tissue that will permit them to thrive. They don't just go looking, though. Instead, they actively prepare the tissue, in one case by co-opting ...

Cancer can be combated with reprogrammed macrophage cells

May 20, 2016

Researchers at Karolinska Institutet have generated antibodies that reprogramme a type of macrophage cell in the tumour, making the immune system better able to recognise and kill tumour cells. The study, which is published ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.